Neural Substrates in Nicotine Withdrawal

2014-07-23 21:12:18 | BioPortfolio


This study will test the hypothesis that a medication called tolcapone (Brand Name: Tasmar) will help reduce cognitive problems that smokers experience when they quit. This study will also determine whether the benefits of this medication differ depending on a smokers' genetic background.


Tolcapone, an FDA-approved treatment for Parkinson's disease, improves cognitive performance in healthy controls with COMT val/val genotypes, putatively by increasing prefrontal dopamine levels. We propose a within-subject double-blind cross-over neuroimaging study of short-term (11 days) treatment with tolcapone (vs. placebo).

Forty-five chronic smokers (15 with val/val genotypes, 15 with met/met genotypes, and 15 with val/met genotypes) will undergo blood oxygenation level dependent (BOLD) fMRI during the two medication periods:

1. after 24 hours of monitored abstinence while on tolcapone, and

2. after 24 hours of monitored abstinence while on placebo (medication order counterbalanced with at least a 10-day washout).

The BOLD fMRI data will be acquired while subjects perform a working memory task (Fractal N-back), a sustained attention task (Continuous Performance Task; CPT), and a response inhibition task (Go/No-Go). The primary outcome is medication effects (within subject) on task-related BOLD activation after 24 hours of abstinence. Changes in behavioral performance and subjective symptoms will be examined in relation to brain activity changes.

The proposed study will provide a critical mechanistic understanding of the role of COMT in abstinence-induced cognitive symptoms that promote smoking relapse. Information obtained in this study may further establish cognitive performance measures as endophenotypes for nicotine dependence.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Tobacco Use Disorder


Tolcapone, Placebo


University of Pennsylvania
United States




University of Pennsylvania

Results (where available)

View Results


Published on BioPortfolio: 2014-07-23T21:12:18-0400

Clinical Trials [1505 Associated Clinical Trials listed on BioPortfolio]

Tolcapone in Obsessive Compulsive Disorder

The proposed study will consist of a 5-week double-blind cross-over study trial of tolcapone in 20 people (ages 18-65). The study will be divided into an initial 2 week phase and a second ...

Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With TBI and MCI

The experimental design is an open-label two-week trial of tolcapone to evaluate which clinical domains are affected by tolcapone treatment and to identify "responders" to tolcapone treatm...

A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone

The purpose of this study is to assess the pharmacokinetic profiles of tolcapone in healthy subjects after administration of one or two oral doses of multiple modified release prototype fo...

Trial of Tolcapone With Oxaliplatin for Neuroblastoma or Medulloblastoma

The purpose of this research study is to evaluate an investigational drug (Tolcapone) alone and in combination with oxaliplatin, for relapsed and refractory neuroblastoma and medulloblasto...

Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control

The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, reduces alcohol drinking and alcohol cue-elicited brain ...

PubMed Articles [6047 Associated PubMed Articles listed on BioPortfolio]


The metabolism of the masking agent tolcapone in the horse has been investigated. This substance was found to have undergone various chemical transformations that produced a large variety of phase I m...

Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?

Among movement disorders and medicine in general, PD is one of the conditions for which there is a greater knowledge of the placebo and nocebo responses. In other movement disorders, the knowledge of ...

The Network Structure of Tobacco Withdrawal in a Community Sample of Smokers Treated with Nicotine Patch and Behavioral Counseling.

Network theories of psychopathology highlight that, rather than being indicators of a latent disorder, symptoms of disorders can causally interact with one another in a network. The present study exam...

Prevalence and patterns of opioid misuse and opioid use disorder among primary care patients who use tobacco.

Current data suggest that opioid misuse or opioid use disorder (OUD) may be over represented among tobacco users. However, this association remains understudied in primary care settings. A better unde...

Pilot Tobacco Treatment Intervention for Women in Residential Treatment for Substance Use Disorder.

To test the feasibility, acceptability, and efficacy of Get Fit and Quit (GFAQ), a community-engaged, holistic tobacco treatment program for women of childbearing age in a residential substance use di...

Medical and Biotech [MESH] Definitions

Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.

The aggregate business enterprise of agriculture, manufacture, and distribution related to tobacco and tobacco-derived products.

Use of TOBACCO (Nicotiana tabacum L) and TOBACCO PRODUCTS.

Items used to aid in ending a TOBACCO habit.

Inhaling and exhaling the smoke of tobacco or something similar to tobacco.

More From BioPortfolio on "Neural Substrates in Nicotine Withdrawal"

Quick Search


Relevant Topic

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Searches Linking to this Trial